Bausch Health Companies Inc and its dermatology business, Ortho Dermatologics announces that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for ARAZLOTM (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older.

ARAZLO is the first tazarotene acne treatment available in a lotion form, and has been shown to provide strong efficacy with favorable tolerability.